[Botulinum toxin in blepharospasm, in hemifacial spasm, and in cervical dystonia: results in 33 patients].
The effects of botulinum toxin type A were studied in 33 patients with dystonia (12 blepharospasms, 10 hemifacial spasms and 11 spasmodic torticollis). A rate scale was used to evaluate the severity of the dystonic movements, before and two weeks after each injection. Among blepharospasm patients, eight were female and four were male; the mean age was 57.7 years; the mean time of the disease duration was four years. Three had familial history for similar disease; nine were essential and three had used neuroleptic drugs (tardive dystonia). The mean dose used was 51.3 U, with a mean time of beneficial effects of 2.8 months. For 22 injections and reinjections, 14 (63.7%) showed an excellent result, five (22.7%) good and three (13.6%) null. In the hemifacial spasm group, eight were female and two male; the mean age was 52.6 years; the mean time of the disease duration was 7.4 years; eight were essential and two post-paralytic. The mean dose used was 32 U. From the total of 15 injections and reinjections, all of them (100%) had an excellent result, with a mean time of beneficial effect of 3.4 months. Among the cervical dystonic patients, eight were male and three female; the mean age was 44.2 years; the mean time of the disease duration was 12.2 years; six had essential dystonia, three had used neuroleptic drugs and two had familial history for similar disease. The mean dose used was 238.6 U, with the mean duration of effect of 3.5 months. From the total of 20 injections and reinjections, 18 (90%) had good result, one (5%) mild and one (5%) null.(ABSTRACT TRUNCATED AT 250 WORDS)
Novis
S A
SA
Servico de Neurologia do Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro, Brasil.
De Mattos
J P
JP
De Rosso
A L
AL
D000328:Adult; D000368:Aged; D001764:Blepharospasm / Q000628:therapy*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D004421:Dystonia / Q000628:therapy*; D005152:Facial Muscles / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009334:Neck Muscles / Q000503:physiopathology*; D012720:Severity of Illness Index; D013035:Spasm / Q000628:therapy*; D013997:Time Factors; D014103:Torticollis / Q000628:therapy
D001905:Botulinum Toxins
Toxina botulínica no blefaroespasmo, no espasmo hemifacial e na distonia cervical: resultados em 33 pacientes.